Corey Salsberg Image

Corey Salsberg

Vice President and Global Head of IP Affairs

Novartis

Corey Salsberg is the Vice President and Global Head of IP Affairs for Novartis, one of the world’s leading innovative biopharmaceutical companies.  He also serves as Secretary of the Board of Directors of the Federal Circuit Bar Association, and as a Board Member of California Lawyers for the Arts.

A graduate of Stanford Law School and Yale University, Mr. Salsberg is a seasoned attorney with over two decades of legal, policy and advocacy experience.  He is one of the founders of the Inventors Assistance Program, a WIPO-WEF initiative that supports under-resourced inventors through pro bono services; Pat-INFORMED, a global database of medicine-related patent information; and the IP PACT, a groundbreaking set of principles that sets forth the patient-centric approach to IP shared by its signatories.

A recognized thought leader and frequent contributor around the world, Mr. Salsberg has testified as an expert before the United States Senate, and frequently appears in a variety of print and online media.

 

Recent Articles by Corey Salsberg

Presenting the Evidence for Patent Eligibility Reform: Part IV – Uncertainty is Burdening Litigants and Courts, Threatening U.S. Competitiveness and National Security

The current unreliability of patent-eligibility law, documented thus far here, here and here, has also created undue burdens on litigants and the courts. In this final installment, we detail how the current unreliability burdens litigants and the courts and how it is a fundamental threat to U.S. competitiveness and national security. Patent infringers now routinely raise Section 101 as a defense, often merely as a strategy to complicate and prolong the litigation, rather than as a good-faith defense with a likelihood of success. For example, one analysis found that, from 2012 to 2014 (when Alice was decided), Section 101 was raised in just two Rule 12(b)(6) motions across the country each year. In the year after Alice, that number rose to 36 motions, and by 2019, accused infringers were filing over 100 such motions each year.

Presenting the Evidence for Patent Eligibility Reform: Part III – Case Studies and Litigation Data Highlight Additional Evidence of Harm

Systemic-level studies and data regarding impact on investment and innovation, as detailed in Part II of this series, are not the only way to demonstrate the substantial harm that the current state of patent eligibility has inflicted on the U.S. innovation ecosystem. Other robust evidence shows that current Section 101 law has harmed innovation by removing the incentives to develop and commercialize particular inventions of public importance. As another form of harm, the vagueness and breadth of the Alice/Mayo framework have also enabled accused infringers to transmogrify Section 101 into a litigation weapon in inappropriate cases that has created unnecessary burdens and costs on innovators and the courts.

Presenting the Evidence for Patent Eligibility Reform: Part II – Harm to R&D Investment, Innovation and U.S. Interests

The muddled state of patent eligibility law has direct and significant negative consequences for U.S. R&D investment, and for innovation in key fields of medical, economic, and strategic importance to the United States and its citizens. Uncertainty reduces R&D investment, as has been well-documented, and reliable patent protection mitigates uncertainty and generates increased R&D investment. As we explained in Part I of this series, the experts overwhelmingly agree on these points.

Presenting the Evidence for Patent Eligibility Reform: Part I – Consensus from Patent Law Experts

Patent eligibility law in the United States is in a state of disarray that has led to inconsistent case decisions, deep uncertainty in the innovative, investment and legal communities, and unpredictable outcomes in patent prosecution and litigation. These facts have been extensively documented in multiple sources, including: the statements of all 12 active judges of the nation’s only patent court, the U.S. Court of Appeals for the Federal Circuit (confirmed prior to October 2021); the findings and reports of the Executive branch across all recent Administrations; the bi-partisan conclusions of Congressional committees; a robust body of academic studies; and at least forty separate witness statements at the 2019 hearings on this issue before the Senate Committee on the Judiciary Subcommittee on IP, including statements from advocates that oppose Section 101 reforms.

Past Events with Corey Salsberg

IPWatchdog Life Sciences Masters™ 2022 (In-Person)


Warning: Undefined variable $event_id in /www/ipwatchdogcom_574/public/wp-content/themes/ipwatchdog/parts/people/speaking-events.php on line 53
October 25 @ 8:00 am - October 26 @ 6:00 pm EDT